Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors
Importance Immune-related adverse events (irAEs) secondary to immune checkpoint
inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell …
inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell …
[HTML][HTML] Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: A meta-analysis
L Lin, Y Liu, C Chen, A Wei, W Li - Frontiers in pharmacology, 2023 - frontiersin.org
Objective: Our study aimed to identify potential correlations between anti-tumor efficacy and
immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC). Methods …
immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC). Methods …
[HTML][HTML] Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: a case report and review of literature
JY Wu, K Kang, J Yi, B Yang - World Journal of Clinical Cases, 2022 - ncbi.nlm.nih.gov
BACKGROUND For advanced lung squamous cell carcinoma, immune checkpoint inhibitors
(ICIs) have been regarded as one of the optimal therapies. While immune-related adverse …
(ICIs) have been regarded as one of the optimal therapies. While immune-related adverse …